R-Bridge Healthcare Fund Secures $50 Million for Motiva® Expansion in Asia

In a significant development for the Asian medical aesthetics market, R-Bridge Healthcare Fund, a prominent affiliate of CBC Group, has announced the closure of a substantial non-dilutive growth financing facility amounting to up to $50 million. This financing is earmarked for Human Investments Ltd. to bolster the expansion of its innovative Motiva® devices in pivotal markets, particularly Korea and China.

Strategic Partnerships and Market Expansion

Human Investments Ltd. stands as the exclusive distributor of Establishment Labs Holdings Inc.'s advanced femtech solutions across Korea and China through its subsidiaries, Motiva Korea and Motiva China. This recent financial support is pivotal as it not only provides growth capital but also integrates a synthetic royalty feature contingent upon reaching specific sales milestones. Such a structure illustrates R-Bridge's commitment to fostering innovative healthcare solutions while mitigating the dilution impact on equity holders.

The proceeds from this funding are expected to capitalize on Motiva Korea's established market leadership in the medical aesthetics and reconstruction sectors within Korea. Furthermore, they will facilitate Motiva China's expansion following the recent National Medical Products Administration (NMPA) approval for the sale of Motiva® devices in China, achieved in November 2023.

Dr. Michael Keyoung, Senior Managing Director and Head of Private Credit and Royalty at CBC Group, expressed his enthusiasm regarding this collaboration, stating, "R-Bridge is pleased to partner with Human Investments Ltd. in supporting the Asian commercial launch of its innovative and differentiated solutions.” He emphasized the importance of promoting high-quality and safe healthcare options in improving health and wellness for all.

Human Investments Ltd.'s Vision

John Lim, the founder and CEO of Human Investments Ltd., shared insights on the brand’s growth trajectory, noting that within just three years of launching in Korea, Motiva® has emerged as the preferred choice among surgeons and consumers, dominating the augmentation and reconstructive mammaplasty fields. “Our aim is to replicate this success across Asia,” he noted. The anticipation surrounding the financing reflects an eagerness to elevate Motiva® beyond its current success, leveraging cutting-edge innovations in science and technology.

R-Bridge's Commitment to Healthcare Innovation

Founded in 2019, R-Bridge Healthcare Fund is dedicated to providing alternative financing avenues for healthcare firms. By focusing on the lucrative realms of royalties, revenue interests, and cash flows from healthcare products, R-Bridge aims to generate attractive returns for investors while simultaneously promoting the proliferation of healthcare solutions across the region. Its inaugural fund launched in 2020 and continues to thrive with investments from its successor fund, RBF II.

With assets under management totaling approximately $9 billion, R-Bridge is strategically positioned within the healthcare sector, including pharmaceuticals, medical technology, and healthcare services. This new funding for Human Investments Ltd. echoes R-Bridge's broader mission to support promising healthcare innovations and expand their market presence, enhancing access to safe and effective medical solutions.

Global Reach of Motiva® Devices

Since their introduction in 2010, Motiva® devices have set benchmarks in breast aesthetics and reconstruction, earning the trust of over four million surgeons and patients across more than 85 countries. The advanced 3D negative imprinting technology used in these devices is known for its superior safety and natural appearance, setting a high standard within the industry. Additionally, recent U.S. FDA approvals have further cemented Motiva's reputation as a leader in breast implant innovation.

As Human Investments Ltd. embarks on this exciting new phase, the backing from R-Bridge Healthcare Fund may prove transformative not only for the company but also for the broader healthcare landscape in Asia, particularly in enhancing women's health and wellness through innovative medical technologies.